urrent options "create a burden and an inability to comply with treatments, which leads to vision loss," Thomas Chalberg, chief executive officer of Avalanche, said in an interview. "Our goal is to bring this to the majority of wet AMD patients who have a need for frequent injections." Avalanche plans a s

urrent options "create a burden and an inability to comply with treatments, which leads to vision loss," Thomas Chalberg, chief executive officer of Avalanche, said in an interview. "Our goal is to bring this to the majority of wet AMD patients who have a need for frequent injections." Avalanche plans a s